Mal-(CH2)5-Val-Cit-PAB-Eribulin

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mal-(CH2)5-Val-Cit-PAB-Eribulin  纯度: 99.97%

Mal-(CH2)5-Val-Cit-PAB-Eribulin 是抗体偶联药物的一部分 (drug-linker conjugate for ADC)，具有抗癌活性，它由抗微管剂Eribulin 和linker Mal-(CH2)5-Val-Cit-PAB 组成。

Mal-(CH2)5-Val-Cit-PAB-Eribulin

Mal-(CH2)5-Val-Cit-PAB-Eribulin Chemical Structure

CAS No. : 2130869-21-3

规格 价格 是否有货 数量
500 μg ￥12500 In-stock
1 mg ￥15800 In-stock
5 mg ￥38500 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

生物活性

Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB[1].

体外研究
(In Vitro)

Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1328.54

Formula

C69H97N7O19
CAS 号

2130869-21-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
参考文献

  • [1]. Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. Patent US20170252458A1.

    [2]. Watanabe K, et, al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4; 10(2): 161-174.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

发表回复